Andere talen VACCINEXPAR

Aandelen

VCNX

US9186403013

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,005 ^USD	+0,84%		+3,41%	-46,22%

02/04	Vaccinex, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
04/03	Vaccinex, Inc. kondigt wijzigingen aan in de leiding, met ingang van 14 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vaccinex, Inc. announced that it has received $1.75 million in funding	12/04
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	02/04
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	29/03
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	28/03
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	27/03
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	27/03
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	27/03
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	04/03
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	04/03
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	21/02
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	21/02
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	21/02
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology	21/02
Vaccinex, Inc. Announces Reverse Stock Split	15/02
Vaccinex Announces Pricing of $3.7 Million PIPE Financing	07/02
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding	07/02
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule	04/12
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update	13/11
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen VACCINEXPAR

Aandelen

VCNX

US9186403013

Andere talen

Filters